Connect with us

Policy

State Bill Requires Lab Testing for CBD Products to Ensure Safety

Published

on

Illinois proposes new CBD Bill

A new bill introduced at Illinois’ legislative department last Wednesday could subject various CBD products sold at Walgreens, other retailers, and gas stations to a regulated laboratory testing.

Rep. Bob Morgan (D-Deerfield) penned the bill that requires every CBD product being sold across the state to meet standard testing requirements developed by the Department of Agriculture.

Answering the need for legislation

CBD-containing products that include oils to caramels to dog treats and bath bombs have taken over the retail market in less than a year. CBD or cannabidiol is the compound extracted from cannabis that does not cause a “high” to its users.

Such items are popular due to CBD being claimed as a miracle remedy for many health conditions like chronic pain and anxiety. However, this substance is still mostly unregulated as of writing. There are a few products that undergo third-party testing as evidence that they contain safe CBD levels, but a standard requirement is yet to be established.

Morgan believes that having such legislation gives the DA the authority to guarantee a product’s safety to consumers.

Chicago CBD company Equilibria Co-Founder Coco Meers stated that there is a wide range of safety and health concerns regarding CBD. Heavy metals, harmful pesticides, and even the incredible amount of CBD in creams might affect the therapeutic benefits of CBD, says Meers.

She also recalled how their search for a supply partner was affected by the lack of regulation and consistency. She stated that everything might be called CBD, but not all of it has the same formulation.

CBD products for sale will be required under the proposed bill to be tested or else be removed from retail stores and online shops, according to Morgan. Projected fines start from $1,000 and rise as violations also add up.

The bill, if passed, will enable the creation of the CBD Safety Fund to which fines will be allocated for enforcement.

Catching up on regulations

President Donald Trump signed legislation late last year that allowed industrial hemp to be cultivated, which is the variety from which CBD is extracted. It has prompted federal regulators to catch up on the many products entering the market.

A study by Brightfield Group, a Chicago-based CBD researching firm, forecasted the industry to grow into a $23.7B market in 2023. Sales for 2019 is also expected to rise to $5B, which is over 700% increase from 2018.

Some states in the US are establishing regulations for CBD products. In Indiana, the labels on such items should have a QR code that contains information like the product ingredients. In California, CBD-containing food will be required by a proposed bill to use hemp cultivated only from licensed industrial hemp growers working under their hemp program.

LeafyQuick Co-Founder Rahul Easwar reiterated that the products sold by their Chicago-based company are tested, even if customers rarely ask about it.

He added that consumers are more curious about flavors available rather than third-party testing, so a statewide regulated test could guarantee a buyer’s safety from harmful products.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Policy

Kamala Harris Jokes About CBD to Make a Serious Point on Cannabis Reform

Published

on

Kamala Harris Jokes About CBD to Make a Serious Point on Cannabis Reform

Senator Kamala Harris (D-CA) joked about how entrepreneurs are promoting cannabidiol or CBD lotion be rubbed on the skin as a cure-all at the same time that people of color struggle to enter the cannabis industry due to being targeted by the nation’s war on drugs.

Harris firmly pointed out social equity as a need in the growing marijuana industry.

Stance on cannabis

When she was still a prosecutor, Harris opposed reform efforts on the cannabis market. As a 2020 presidential candidate for the Democrats, she now recognizes the necessity of legislation that fully legalizes it. She said in her Cosmopolitan interview that those under prohibition enforcement should be allowed participation in the burgeoning market.

Harris stated that America’s mass incarceration system is a source of shame and is the reason for the incarceration, in particular, of brown and black men due to the failure of the war on drugs. She said that this is why she supports the legalization of marijuana and wants an equitable market when it happens.

However, Harris also talked about the cannabis industry, and how CBD is poised as a miracle remedy that can cure every problem by simply rubbing it all over the body. She noted how sellers are making a lot of money selling weed, calling the industry a massive cash cow.

She went on to mention brown and black men who are tagged as felons by selling the same. She called it unfair and wrong and a travesty.

A reform plan for marijuana

Harris further laid out her reform plans for the cannabis market, citing previously incarcerated folks who were convicted of a felony be considered for expungement. She also plans to prioritize them should they want to return to selling cannabis. She added that they should be first in line if marijuana legalization will be realized.

The candidate has sponsored a Senate bill that moves to de-schedule cannabis federally and offers reinvestments and expungements for people and communities affected by the drug war.

However, Harris received criticism for being previously opposed to the marijuana reform. In a skit last September, Saturday Night Live featured the US’ “cool aunt” who gives out weed but later on arrests those who were holding the substance in their possession.

Representative Tulsi Gabbard (D-HI) also slammed Harris during a Democratic debate for being instrumental to the incarceration of low-level cannabis felons during her stint as a prosecutor.

Another presidential candidate, Senator Cory Booker (D-NJ), scrutinized Harris, for taking a swipe at her being a past user of cannabis.

Cannabis sativa L., the source plant species for marijuana and hemp variety, is where cannabidiol or CBD is extracted from. This active component is said to have therapeutic benefits and is marketed as an infusion to many products, including skincare, makeup, pet items, and more. There is a serious lack of studies and clinical trials to support the claims, but users patronize CBD due to its alleged effectiveness.

Continue Reading

Policy

NYS CBD Regulation in Limbo as People Wait for Governor’s Signature

Published

on

NYS CBD Regulation in Limbo as People Wait for Governor’s Signature

The United States Department of Agriculture (USDA) finally released its regulations on CBD to give more explicit federal guidelines on hemp cultivation that produces CBD.

In New York, however, lines are still blurry as the bill approved by the State Legislature that aims to regulate CBD across the state is yet to be enacted upon by Gov. Andrew Cuomo.

Wild West in CBD Market

Jen Metzger, the Senate bill sponsor, expressed her hope that the NY Governor will sign the bill soon. She sponsored the proposed legislation to regulate cannabidiol, a compound derived from the hemp plant variety of Cannabis sativa L.

It’s the same source plant as marijuana, which has high amounts of tetrahydrocannabinol or THC, the chemical responsible for the psychoactive effects of the illegal substance.

According to Metzger, who is Hudson Valley Democrat, it’s the Wild West in the CBD market since there is no regulation of the said product.

The bill proposes routine testing for CBD products sold across New York and observance of proper labeling to prevent confusion and misunderstanding about the product’s ingredients and additives. It also includes guidelines for New York farmers regarding hemp cultivation and profit share.

Risks of unregulated CBD

CBD is currently in a legal gray area. The 2018 Farm Bill essentially legalized hemp-derived CBD with less than 0.3% of THC content and is also federally allowed for sale.

However, CBD-containing beverages and food are still illegal for the market. The New York City Health Department stopped restaurants and eateries in the state from selling CBD edibles and drinks since consumables with CBD have not yet been approved as a safe food additive.

Recently, a mysterious THC-related illness affected thousands across the country and claimed dozens of lives due to the use of a particular vape product. Metzger stated that CBD is not a common vaping ingredient. She relayed her concerns about the lack of regulation causing more illnesses since products may bear unfounded claims in the packaging.

Metzger pointed out that worrying about CBD might be necessary due to a lack of quality standards.

CBD is commonly used to relieve stress and help in insomnia and anxiety. It has more claimed therapeutic benefits, and the FDA has approved a CBD-containing drug used to treat seizure disorders in children.

Calls for more CBD studies

Metzger encourages more research on cannabidiol and its alleged effects, whether positive or negative.

Metzger and co-legislator Donna Lupardo presented the measure during a 2019 legislative session as soon as they realized that the comprehensive bill being worked on was not winning an approval. This bill was supposedly for the legalization of adult recreational marijuana use.

Metzger and Lupardo are the chairperson of their respective agricultural committees.

Gov. Cuomo has allied with three neighboring states to work on a comprehensive bill about vaping and cannabis use, which could be up for voting in 2020. However, Metzger said a concrete CBD regulation on or before the year ends still necessary.

Continue Reading

Policy

Chuck Schumer Calls for FDA to Hasten CBD Rules Issuance

Published

on

Chuck Schumer requests faster issuance of guidelines

Chuck Schumer (D-NY), Senate minority leader, speaks about his request to the Food and Drug Administration or FDA to expedite the issuance of guidelines regarding hemp-derived CBD and its lawful marketing.

Schumer made a statement during a press call last Wednesday to call for regulatory clarity that is currently hampering the growth of the cannabidiol industry. He also mentioned the federal legalization of hemp and hemp-derived products in the 2018 Farm Bill.

However, the FDA is yet to publish official rules that allow sellers to market their products. In New York, most hemp cultivators also produce cannabidiol, according to Schumer.

Appealing to the FDA

Schumer cited a letter that he and colleagues in the Senate addressed to Ned Sharpless, an FDA acting commissioner. They collectively asked to show the agency’s outline regarding its plans for an official CBD regulatory framework and the timeline of finalization and implementation of enforcement policies concerning the substance. The group asked for an answer within 90 days.

According to Schumer, the CBD industry is a potential billion-dollar market in New York, which could bring in countless jobs and improved the economy along with its rise. However, he also stated that for these to be realized, critical players in the industry, such as the farmers, producers, consumers, and sellers should have a strict set of rules to follow.

He called on the FDA to perform its duty promptly and issue the guidance on CBD and its classification, quality, marketing, labeling, and sales.

Schumer believes that the FDA regulations on CBD are critical in the development of the industry and to protect consumers by setting stringent quality control benchmarks.

FDA stance on CBD

The FDA has expressed its awareness of the Congress’ request for CBD regulation amid the legalization of hemp. However, the agency points out that there are specific regulatory challenges they are still working to overcome.

The Cannabidiol or CBD-containing product that FDA recognizes is the approved Epidiolex medication. It is a prescription drug used to treat intractable epilepsy. CBD edibles, on the other hand, are yet to be FDA-approved and may need alternative pathways for regulation.

Scott Gottlieb, a former FDA commissioner, stated in an interview that the federal government should include themselves in state marijuana program regulation. He suggested that congressional involvement may be needed to make CBD marketing lawful if they want to hasten the process of developing rules.

It’s not only Schumer that reached out to the FDA. Mitch McConnell (R-KY), Senate majority leader, called on the FDA to release guidelines on enforcement discretion so producers, manufacturers, and owners in the CBD industry can do business without worrying about being penalized. McConnel led the inclusion of hemp legalization in the said agriculture legislation.

FDA stated that they are particular about CBD companies that make baseless claims about the therapeutic properties of CBD, which the agency considers to be highly inappropriate. The FDA, along with the Federal Trade Commission, issued a warning notice to a particular CBD business that violated the standard.

Continue Reading

Trending